Module 2: Clinical Trial Data for Current and Emerging BCMA-Targeting Agents
Primary Audience:
This activity is intended to meet the educational needs of hematologists/ oncologists involved in the treatment of patients with RRMM.
This module will cover recently approved and emerging bispecific antibodies and approved CAR T-cell therapies.
Syed Abbas Ali, MBBS
Assistant Professor or Oncology
Department of Oncology, Hematologic Malignancies
Johns Hopkins School of Medicine
Baltimore, MD
Dr. Syed Abbas Ali is a medical oncology specialist in Baltimore, caring for patients with cancer.
Dr. Ali earned his M.B.B.S. at The Aga Khan University. He completed his residency at the University of Arkansas for Medical Sciences and performed a fellowship in medical oncology at the National Institutes of Health.
1.
Use knowledge of the latest clinical data on BCMA therapies in RRMM, including key trials, efficacy insights, and side effect profiles in clinical decision making.
